NAD+ and sirtuins: how the enzymes use NAD+ and what research examined

Prepared by: Research Desk. Sources are linked for verification.

Sirtuins are probably the most quoted reason NAD+ became a research and marketing topic. The usual story is short: NAD+ "fuels" sirtuins, sirtuins are linked to longevity, so more NAD+ must mean more sirtuin activity. Each link in that chain is a separate scientific claim, and the evidence behind each is very different. This explainer covers the biochemistry of how sirtuins actually use NAD+. It explains why other enzymes compete for the same molecule, what cell and animal studies examined, and where the debate over sirtuin activators and lifespan stands.

For the wider picture of NAD+ synthesis, precursors and human trials, see our NAD+ guide. This page stays narrowly on the enzymes.

What a sirtuin is, in biochemical terms

Sirtuins are a family of enzymes that remove chemical tags, most famously acetyl groups, from lysine residues on proteins. Removing an acetyl group can change how a protein behaves. It can affect how tightly a histone holds DNA, whether a transcription factor is active, or how a metabolic enzyme performs. Reviews describe sirtuins as regulators that link the cell's metabolic state to gene expression and protein function [1][2].

What makes sirtuins unusual is that they cannot do this job without NAD+. Many deacetylase enzymes simply use water to cut the acetyl group off. Sirtuins instead consume one molecule of NAD+ per reaction. For that reason, researchers regard NAD+ availability as a possible control point for sirtuin activity [1][3].

The reaction: NAD+ in, nicotinamide out

In a typical sirtuin deacetylation:

1. The enzyme binds an acetylated protein and a molecule of NAD+.

2. NAD+ is split, and nicotinamide (NAM) is released.

3. The acetyl group is transferred from the protein onto the ADP-ribose part of the original NAD+, forming an acetylated ADP-ribose product.

4. The deacetylated protein is released.

So the products are a modified protein, NAM and an acyl-ADP-ribose molecule [1][2]. NAD+ here works as a co-substrate that gets used up. That is different from its familiar role as an electron carrier, where NAD+ and NADH cycle back and forth without being destroyed [3].

Nicotinamide as product and brake

The NAM released by the reaction can inhibit sirtuins, so the enzyme's own product feeds back on it [1][2]. Cells do not discard this NAM. They recycle it back into NAD+ through the salvage route, which links sirtuin activity directly to recycling capacity. We cover that route step by step in the NAD+ salvage pathway.

Seven mammalian sirtuins, different jobs

Mammals have seven sirtuins, SIRT1 to SIRT7. All depend on NAD+, but they sit in different parts of the cell and act on different targets [1][4]:

Several sirtuins remove other acyl groups as well as acetyl groups, which is why "deacylase" is often the more accurate term [1]. SIRT1 is the best studied. Reviews cover its links to mitochondrial regulation [7], inflammatory signalling [8] and cellular senescence [9]. Much of that literature, however, comes from cell lines and genetically modified mice.

Competition for the NAD+ pool: PARPs and CD38

Sirtuins are not the only enzymes that consume NAD+. Two other families draw on the same pool [3][5]:

• PARPs (poly-ADP-ribose polymerases) use NAD+ to build ADP-ribose chains on proteins during the response to DNA damage. Heavy DNA damage can drive substantial PARP activity and NAD+ use.

• CD38 is an enzyme found abundantly on immune cells. It breaks NAD+ down, releasing NAM and signalling molecules.

Because all three families compete for the same molecule, changes in one can affect NAD+ availability for the others. Reviews of NAD+ homeostasis describe animal experiments in which reducing PARP1 or CD38 activity was associated with higher tissue NAD+ and altered sirtuin activity [3][5]. Strømland and colleagues frame ageing-related NAD+ changes as a balance question. They ask whether lower levels reflect reduced synthesis, increased consumption by enzymes such as CD38 and PARPs, or both [5].

Concentration is not the same as flux

A common assumption is that a lower NAD+ concentration means less NAD+ is available for sirtuins. A 2021 isotope-tracing study in mice tested this directly. It found that NAD+ flux, meaning the rate at which NAD+ is made and consumed, was maintained in aged mice even though tissue concentrations were lower [6]. That result is a useful caution. A single static measurement, whether in tissue or blood, does not show how fast sirtuins and other enzymes are turning NAD+ over. This matters when interpreting any NAD+ test result, as discussed in reading an NAD+ test report.

What cell and animal studies examined

Much of the NAD+–sirtuin literature comes from experimental models:

• Precursor studies in mice. In a 2012 mouse study, nicotinamide riboside raised tissue NAD+ and was associated with increased SIRT1 and SIRT3 activity markers and oxidative metabolism in animals on a high-fat diet [10].

• Muscle and exercise. Reviews of skeletal muscle describe how NAD+ levels, sirtuin activity and protein acetylation shift with age and exercise in rodent models. They also note that tissue-specific findings do not always generalise [11].

• Senescence and inflammation. Cell and animal work has examined how sirtuin signalling relates to cellular senescence [9] and how SIRT1 interacts with inflammatory transcription factors [8].

• Epigenetics. Reviews of sirtuins and longevity discuss how sirtuin-driven histone deacetylation could influence chromatin state, mostly drawing on yeast, worm, fly and mouse data [4].

These findings support a biological link between NAD+ availability and sirtuin function in model systems. They do not by themselves show that changing NAD+ levels changes sirtuin activity in human tissues, or that any such change alters ageing outcomes [2][5].

The activator debate and lifespan findings

Starting in the 2000s, compounds such as resveratrol and synthetic molecules were described as sirtuin activators. A 2012 review of the patent literature catalogued many chemical classes claimed to activate SIRT1 [12]. The field has been contentious. Disputes have centred on whether apparent activation measured in test-tube assays depended on assay design. Researchers have also debated whether metabolic findings in mice on high-fat diets reproduce across laboratories and on normal diets [12].

Lifespan results from simple organisms have also been debated and have not translated uniformly across species. Historical overviews of ageing research present sirtuins as one strand of geroscience. They describe the topic as a hypothesis with mixed experimental support rather than an established human mechanism [13]. The careful summary is this: sirtuins are well-characterised NAD+-dependent enzymes. The stronger claim that activating them reliably extends lifespan is not settled.

What human research has and has not measured

Human data on NAD+ and sirtuins are thinner and mostly indirect. A study of human tissue samples reported age-associated changes in NAD+ levels and oxidative-stress markers [14]. In a small crossover trial in healthy middle-aged and older adults, nicotinamide riboside raised NAD+ in blood cells [15]. A randomized trial of NMN in women with prediabetes reported changes in muscle insulin sensitivity and signalling measures [16]. None of these studies established sirtuin activation in people as the mechanism behind its measured outcomes. A 2026 systematic review of preclinical and human studies noted the gap between consistent rises in NAD+ metabolites and less consistent findings on other outcomes [17]. Our nicotinamide riboside research summary covers those trials in more detail. For how regulators classify these ingredients, see NAD+ and NMN legal status.

Tools for comparing NAD+ tests

Because sirtuin research hinges on NAD+ availability, readers often ask how NAD+ is measured outside a research lab. Consumer and lab tests differ widely. Useful neutral criteria include:

• Sample type. Whole blood, dried blood spot or isolated cells. Results from different sample types are not interchangeable.

• Analytical method. Mass spectrometry (LC-MS) or enzymatic cycling assays, and whether the provider publishes validation data.

• What is reported. NAD+ alone, NAD+/NADH ratio, or a broader panel of related metabolites such as NAM.

• Reference ranges. How the comparison population was defined, and whether that is stated.

• Price and data practices. Transparent pricing, turnaround time and a clear data-privacy policy.

Our NAD+ test buyer's guide compares formats using these criteria.

No current consumer test measures sirtuin activity itself. These tests report NAD+-related metabolite levels at one point in time.

For background reading, our evidence-graded reading list on sirtuins and aging grades books by how closely they track the primary literature.

Frequently asked questions

Do sirtuins need NAD+ to work?

Yes. Sirtuins consume one NAD+ molecule for each deacylation reaction, splitting it and releasing nicotinamide [1]. This dependence is why NAD+ availability is studied as a possible regulator of their activity.

Why does nicotinamide matter in sirtuin research?

Nicotinamide is a product of the sirtuin reaction and can inhibit the enzyme, creating a feedback loop [1][2]. Cells recycle it into NAD+ through the salvage pathway.

Do PARPs and CD38 reduce NAD+ available to sirtuins?

They draw on the same NAD+ pool. Animal studies summarised in reviews linked reduced PARP1 or CD38 activity with higher NAD+ and altered sirtuin activity [3][5]. Whether the same balance holds in human tissues is less well characterised.

Is it proven that sirtuin activators extend lifespan?

No. Lifespan findings vary across species and laboratories, and earlier activator results were debated on methodological grounds [12][13]. No human lifespan data exist.

Related on this site

• NAD+, measured properly

• NAD+ explained: biochemistry, precursors, testing and human evidence

• The NAD+ salvage pathway: how cells recycle NAD+

• NMN vs NAD+: precursor and coenzyme, explained

• Reading an NAD+ test report: units, sample types and reference ranges

• About NAD Peptide Labs: how this site works and disclosures

Last updated: 21 October 2026.

Not medical advice. This page reports published research and regulatory records for information only.

Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.

Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.